Search Results

Matthew Thompson, MD, Named Endologix’s President and CEO

November 10, 2021—Endologix LLC announced it has appointed Dr. Matthew Thompson as its new President and Chief Executive Officer and to the Board of Directors.

Endologix Appoints Prof. Matthew Thompson as Chief Medical Officer

October 25, 2016—Endologix, Inc. announced the appointment of Matthew Thompson, MD, as Chief Medical Officer effective December 2016.

ASCEND Data Support Endologix Nellix EVAS System to Treat Juxtarenal and Pararenal AAAs

April 28, 2016—Endologix, Inc. announced the first data presentation from the ASCEND Registry (Aneurysm Study for Complex Abdominal Aortic Aneurysm [AAA]: Evaluation of Nellix Durability), a physician-initiated registry of the Nellix EndoVascular Aneurysm Sealing (EVAS) system used with aortic branch stent grafts for the treatment of patients with complex AAAs. In November, the company announced the start of the registry, which is being conducted outside the United States.

Endologix Completes Enrollment in EVAS FORWARD—GLOBAL Registry of Nellix System

September 29, 2014—Endologix announced that it has completed patient enrollment in the EVAS FORWARD—GLOBAL registry, which enrolled 300 patients treated with the company’s Nellix endovascular aneurysm sealing (EVAS) system at centers in Europe and New Zealand from October 2013 to September 2014.

Physician-Initiated ASCEND Registry to Evaluate the Endologix Nellix EVAS System

November 18, 2015—Endologix, Inc. announced the start of a physician-initiated registry of the Nellix endovascular aneurysm sealing (EVAS) system used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms (AAAs).